Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation

Borje S. Andersson

doi:10.1016/j.leukres.2015.11.015

Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation

Borje S. Andersson

Stem Cell Transplantation

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	5-6
Number of pages	2
Journal	Leukemia Research
Volume	41
DOIs	https://doi.org/10.1016/j.leukres.2015.11.015
State	Published - Feb 1 2016

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2015.11.015

Cite this

Andersson, B. S. (2016). Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation. Leukemia Research, 41, 5-6. https://doi.org/10.1016/j.leukres.2015.11.015

Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation. / Andersson, Borje S.
In: Leukemia Research, Vol. 41, 01.02.2016, p. 5-6.

Research output: Contribution to journal › Editorial › peer-review

Andersson, BS 2016, 'Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation', Leukemia Research, vol. 41, pp. 5-6. https://doi.org/10.1016/j.leukres.2015.11.015

Andersson BS. Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation. Leukemia Research. 2016 Feb 1;41:5-6. doi: 10.1016/j.leukres.2015.11.015

Andersson, Borje S. / Fludarabine-IV busulfan, dose-intensity and progression-free survival : Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation. In: Leukemia Research. 2016 ; Vol. 41. pp. 5-6.

@article{b6d1ef2940754db2aac2d6383f4bf3b2,

title = "Fludarabine-IV busulfan, dose-intensity and progression-free survival: Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation",

author = "Andersson, {Borje S.}",

year = "2016",

month = feb,

day = "1",

doi = "10.1016/j.leukres.2015.11.015",

language = "English (US)",

volume = "41",

pages = "5--6",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Fludarabine-IV busulfan, dose-intensity and progression-free survival

T2 - Are we finally finding the way to reach a consensus opinion? Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the acute leukemia working party of the European group for blood and marrow transplantation

AU - Andersson, Borje S.

PY - 2016/2/1

Y1 - 2016/2/1

UR - http://www.scopus.com/inward/record.url?scp=84957848427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957848427&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2015.11.015

DO - 10.1016/j.leukres.2015.11.015

M3 - Editorial

C2 - 26733443

AN - SCOPUS:84957848427

SN - 0145-2126

VL - 41

SP - 5

EP - 6

JO - Leukemia Research

JF - Leukemia Research

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this